Improving Community Oncology Practices Through the American Oncology Network
June 20th 2019The American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
Watch
VISION Trial Demonstrates Liquid Biopsy Is Comparable to Tissue Biopsy for NSCLC
June 20th 2019Paul K. Paik, MD, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with non–small cell lung cancer harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.
Watch
Examining Recent PACIFIC Trial Updates for Durvalumab in Locally Advanced NSCLC
June 19th 2019David Spigel, MD, chief scientific officer of Sarah Cannon Research Institute, gives a recap on the phase III PACIFIC study, with facts and perceptions surrounding the latest data that study researchers reported during the 2019 ASCO Annual Meeting.
Watch
Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHL
June 19th 2019David J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
Watch
ACCC Addresses Education Needs for Community Oncologists
June 18th 2019David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with <em>Targeted Oncology</em>at the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care. <br />
Watch
Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC
June 18th 2019Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.
Watch
Nilotinib Benefits Relapsed Patients With CML After Treatment Discontinuation
June 18th 2019Jorge E. Cortes, MD, discusses the results from the ENESTFreedom study, which evaluated the use of nilotinib as a treatment for patients with BCR-ABL1–positive chronic myeloid leukemia in the chronic phase.<br />
Watch